Trends in liposomal nanocarrier strategies for the oral delivery of biologics.
Nanomedicine (Lond)
; 16(20): 1813-1832, 2021 08.
Article
em En
| MEDLINE
| ID: mdl-34269068
ABSTRACT
The number of approved macromolecular drugs such as peptides, proteins and antibodies steadily increases. Since drugs with high molecular weight are commonly not suitable for oral delivery, research on carrier strategies enabling oral administration is of vital interest. In past decades, nanocarriers, in particular liposomes, have been exhaustively investigated as oral drug-delivery platform. Despite their successful application as parenteral delivery vehicles, liposomes have up to date not succeeded for oral administration. However, a plenitude of approaches aiming to increase the oral bioavailability of macromolecular drugs administered by liposomal formulations has been published. Here, we summarize the strategies published in the last 10 years (vaccine strategies excluded) with a main focus on strategies proven efficient in animal models.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Produtos Biológicos
/
Lipossomos
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Nanomedicine (Lond)
Ano de publicação:
2021
Tipo de documento:
Article